$1.08
0.065.88%
Last update: Nov 10, 4:27 AM
Lineage Cell Therapeutics Inc
LCTXAMEX
Lineage Cell Therapeutics fell 40.3% from $1.81 to $1.08, behind the S&P 500's +10.5%. Its worst day was Sep 23 (−8.0%), and its low came Oct 1 at $0.90.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Lineage Cell Therapeutics shares rose 14.3%, while the S&P 500 fell 0.8%.
+14.3%, the year's best day · S&P 500 −0.8%
Lineage Cell Therapeutics closed at its highest level of the year, 8.3% above where the year started.
Story events cover the past 12 months · Times ET
+3.2% · S&P 500 −0.6%
EPS of $0.00 beat the $-0.05 estimate on $6.6M revenue (est. $2.1M).
+0.5% · S&P 500 −1.3%
EPS of $-0.03 beat the $-0.03 estimate on $1.7M revenue (est. $3.1M).
−3.8% · S&P 500 +0.6%
EPS of $-0.03 missed the $-0.02 estimate on $1.1M revenue (est. $5.2M).
−2.7% · S&P 500 +0.6%
Lineage Cell Therapeutics closed at its lowest level of the year, 50.0% below where the year started.
−5.4% · S&P 500 +0.2%
Where it ended: a close of $1.08 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.03, revenue est. $2.3M).
Nothing in the past 12 months.
All LCTX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LCTX and SPY from Benzinga historical bars. Not investment advice.
